CA3033239A1 - Inhibiteurs spiro bicycliques de l'interaction menine-mll - Google Patents

Inhibiteurs spiro bicycliques de l'interaction menine-mll Download PDF

Info

Publication number
CA3033239A1
CA3033239A1 CA3033239A CA3033239A CA3033239A1 CA 3033239 A1 CA3033239 A1 CA 3033239A1 CA 3033239 A CA3033239 A CA 3033239A CA 3033239 A CA3033239 A CA 3033239A CA 3033239 A1 CA3033239 A1 CA 3033239A1
Authority
CA
Canada
Prior art keywords
group
optionally substituted
4alkyl
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033239A
Other languages
English (en)
Inventor
Patrick Rene Angibaud
Vineet PANDE
Barbara HERKERT
Daniel Jason Krosky
Olivier Alexis Georges Querolle
Isabelle Noelle Constance Pilatte
Aaron Nathaniel PATRICK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3033239A1 publication Critical patent/CA3033239A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des agents pharmaceutiques utiles pour la thérapie et/ou la prophylaxie chez un mammifère, et en particulier des composés spiro bicycliques, une composition pharmaceutique comprenant de tels composés, et leur utilisation en tant qu'inhibiteurs d'interactions ménine/protéine MLL/protéine, utiles pour le traitement de maladies telles que le cancer, le syndrome myélodysplasique (MDS) et le diabète.
CA3033239A 2016-09-14 2017-09-13 Inhibiteurs spiro bicycliques de l'interaction menine-mll Pending CA3033239A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394295P 2016-09-14 2016-09-14
US62/394,295 2016-09-14
EP16192431 2016-10-05
EP16192431.1 2016-10-05
PCT/EP2017/073004 WO2018050686A1 (fr) 2016-09-14 2017-09-13 Inhibiteurs spiro bicycliques de l'interaction ménine-mll

Publications (1)

Publication Number Publication Date
CA3033239A1 true CA3033239A1 (fr) 2018-03-22

Family

ID=57083210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033239A Pending CA3033239A1 (fr) 2016-09-14 2017-09-13 Inhibiteurs spiro bicycliques de l'interaction menine-mll

Country Status (4)

Country Link
CA (1) CA3033239A1 (fr)
EA (1) EA201990699A1 (fr)
TW (1) TWI738864B (fr)
WO (1) WO2018050686A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112771055A (zh) * 2018-08-08 2021-05-07 大日本住友制药株式会社 光学活性桥接哌啶衍生物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (fr) 2015-06-04 2016-12-08 Kura Oncology, Inc. Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
JP6919977B2 (ja) 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法
SG11201807834WA (en) 2016-03-16 2018-10-30 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
EP3601249A4 (fr) 2017-03-24 2020-12-16 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
BR112020012461A2 (pt) * 2017-12-20 2020-11-24 Janssen Pharmaceutica Nv inibidores exo-aza espiro da interação menin-mll
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
CN112585140B (zh) 2018-08-27 2023-07-04 住友制药株式会社 光学活性氮杂双环衍生物
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
WO2021060453A1 (fr) * 2019-09-27 2021-04-01 大日本住友製薬株式会社 Dérivé d'amine secondaire optiquement actif réticulé
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
CN117396476A (zh) 2021-06-01 2024-01-12 詹森药业有限公司 取代的苯基-1H-吡咯并[2,3-c]吡啶衍生物
EP4347600A1 (fr) 2021-06-03 2024-04-10 JANSSEN Pharmaceutica NV Pyridazines ou 1,2,4-triazines substituées par des amines spirocycliques
WO2022262796A1 (fr) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv Sel de bésylate (r)-n-éthyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-méthoxyéthyl)(méthyl)amino)-2-m éthylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide pour le traitement de maladies telles que le cancer
WO2024033479A1 (fr) * 2022-08-11 2024-02-15 Remynd N.V. Dérivés d'(aza)spiroheptane pour le traitement de troubles neurodégénératifs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
CA2904612A1 (fr) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprenant des composes thienopyrimidine et thienopyridine et procedes d'utilisation associes
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
US20190010167A1 (en) 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112771055A (zh) * 2018-08-08 2021-05-07 大日本住友制药株式会社 光学活性桥接哌啶衍生物
CN112771055B (zh) * 2018-08-08 2023-10-20 住友制药株式会社 光学活性桥接哌啶衍生物

Also Published As

Publication number Publication date
WO2018050686A1 (fr) 2018-03-22
TWI738864B (zh) 2021-09-11
EA201990699A1 (ru) 2019-09-30
TW201823250A (zh) 2018-07-01

Similar Documents

Publication Publication Date Title
CA3033239A1 (fr) Inhibiteurs spiro bicycliques de l'interaction menine-mll
CN109715634B (zh) Menin-mll相互作用的稠合二环抑制剂
EP3512857B1 (fr) Inhibiteurs spiro-bicyclique de menin-mll-interaction
EP3145929B1 (fr) Composés 5-chloro -2-difluorométhoxyphényl pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak
WO2018109088A1 (fr) Inhibiteurs d'azépane de l'interaction ménine-mll
US11530226B2 (en) Azepane inhibitors of menin-MLL interaction
US20220227786A1 (en) Spiro Bicyclic Inhibitors Of Menin-MLL Interaction
EA045364B1 (ru) Спиробициклические ингибиторы взаимодействия менин-mll
CN113087724A (zh) 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
EA045404B1 (ru) Конденсированные бициклические ингибиторы взаимодействия менин-mll
OA16957A (en) PDE9 inhibitors with imidazo triazinone backbone.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220906

EEER Examination request

Effective date: 20220906

EEER Examination request

Effective date: 20220906

EEER Examination request

Effective date: 20220906